Evidence map›Paper›PMID 35231068›Full record

ArticlePLoS pathogens2022

Correlative proteomics identify the key roles of stress tolerance strategies in Acinetobacter baumannii in response to polymyxin and human macrophages.

Zhi Ying Kho, Mohammad A K Azad, Mei-Ling Han, Yan Zhu, Cheng Huang, Ralf B Schittenhelm, Thomas Naderer, Tony Velkov, Joel Selkrig, Qi Tony Zhou and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Disruption ofVirulence · 2026
    Article
  2. Article
  3. IntracellularProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Zhi Ying KhoBiomedicine Discovery Institute, Infection Program and Department of Microbiology, Monash University, Clayton, Victoria, Australia.
Mohammad A K AzadBiomedicine Discovery Institute, Infection Program and Department of Microbiology, Monash University, Clayton, Victoria, Australia.
Mei-Ling HanBiomedicine Discovery Institute, Infection Program and Department of Microbiology, Monash University, Clayton, Victoria, Australia.
Yan ZhuBiomedicine Discovery Institute, Infection Program and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-7342-3782
Cheng HuangMonash Proteomics & Metabolomics Facility, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Ralf B SchittenhelmMonash Proteomics & Metabolomics Facility, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Thomas NadererBiomedicine Discovery Institute, Infection Program, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Tony VelkovDepartment of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia.
Joel SelkrigEuropean Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
Qi Tony ZhouDepartment of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana, United States of America.ORCID 0000-0002-1438-6990
Jian LiBiomedicine Discovery Institute, Infection Program and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-7953-8230
Australian Regenerative Medicine Institute · AUMonash University · AUEuropean Molecular Biology Laboratory · DEPurdue University West Lafayette · USThe University of Melbourne · AU

Funding

Advancing innovative therapies against pandrug-resistant Gram-negative superbugsR01AI146160 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2019 to 2023
$3.2M
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems ApproachR01AI132681 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2017 to 2020
$2.4M
NIAID NIH HHS R01 AI132681NIAID NIH HHS R01 AI146160
6 · The paper itself

Abstract

The opportunistic pathogen Acinetobacter baumannii possesses stress tolerance strategies against host innate immunity and antibiotic killing. However, how the host-pathogen-antibiotic interaction affects the overall molecular regulation of bacterial pathogenesis and host response remains unexplored. Here, we simultaneously investigate proteomic changes in A. baumannii and macrophages following infection in the absence or presence of the polymyxins. We discover that macrophages and polymyxins exhibit complementary effects to disarm several stress tolerance and survival strategies in A. baumannii, including oxidative stress resistance, copper tolerance, bacterial iron acquisition and stringent response regulation systems. Using the spoT mutant strains, we demonstrate that bacterial cells with defects in stringent response exhibit enhanced susceptibility to polymyxin killing and reduced survival in infected mice, compared to the wild-type strain. Together, our findings highlight that better understanding of host-pathogen-antibiotic interplay is critical for optimization of antibiotic use in patients and the discovery of new antimicrobial strategy to tackle multidrug-resistant bacterial infections.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialHumansMacrophagesMiceMicrobial Sensitivity TestsPolymyxinsProteomicsAnti-Bacterial AgentsPolymyxins

Identifiers

PMID35231068
PMCPMC8887720
OpenAlexW4214661877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.